BSX

Boston Scientific's stock price has fallen 55.7% over the past year, trading near its 52-week low around $43.71 as of September 22, 2026. Key events impacting the stock include a cyberattack in August 2026 that disrupted operations and led to the withdrawal of Q3 and full-year 2026 forecasts, causing a stock drop and a lowered price target from Wells Fargo. Slowing growth in key segments like the WATCHMAN device and electrophysiology led management to cut 2026 guidance twice. Analyst downgrades and price target cuts followed a lowered full-year outlook after Q1 2026 earnings, with Citi downgrading the stock to Neutral in September 2026. The acquisition of Penumbra for approximately $14.5 billion, expected to be completed in 2026, has also been noted as a factor in the stock's valuation.